

**JUNO THERAPEUTICS, INC.
SCIENTIFIC COMMITTEE CHARTER**

This Scientific Committee Charter (this “Charter”) was adopted by the Board of Directors (the “Board”) of Juno Therapeutics, Inc., a Delaware corporation (the “Company”), on July 8, 2014.

I. Purpose

The purpose of the Scientific Committee (the “Committee”) of the Company’s Board is to assist the directors in fulfilling their responsibilities by reviewing and evaluating the Company’s research strategy and research, development and clinical programs. To accomplish this purpose, the Committee will review and monitor the science, processes and procedures, and infrastructure underlying the Company’s major discovery and clinical development programs, and make recommendations to the Board and/or management regarding the same.

In addition to the specific powers and responsibilities delegated to the Committee in this Charter, the Committee shall also carry out and may exercise any other powers or responsibilities as are assigned by law, the Company’s charter or bylaws, or as may be delegated to it by the Board from time to time.

II. Membership

The Committee shall consist of at least three members of the Board, none of whom shall be an employee of the Company; provided, that if at any time there is a vacancy on the Committee, then the Committee may consist of two members until the earlier of the Company’s next annual stockholders meeting or one year from the occurrence of the vacancy, unless the next annual stockholders meeting occurs within 180 days following the occurrence of the vacancy, in which case the Committee may consist of two members until the end of such 180-day period. Each member of the Committee shall have sufficient scientific and/or medical expertise to review and evaluate appropriately the Company’s clinical programs and research and development projects.

III. Meetings and Procedures

The Committee shall meet at least once annually, and on such other occasions as the members of the Committee may from time to time determine. Meetings of the Committee shall be held upon call by the Chairperson of the Board or the Chairperson of the Committee.

The Committee shall appoint a Secretary of the Committee from time to time.

A quorum of the Committee shall consist of a majority of the members of the Committee in office at the time of any meeting and the vote of a majority of the members of the Committee present at the time of a vote, if a quorum is present at that time, shall be the act of the Committee. The Chairperson of the Committee (or in his or her absence, another member designated by the Chairperson of the Committee), shall preside at each meeting of the Committee and set the agendas for Committee meetings.

All non-management directors that are not members of the Committee may attend and observe meetings of the Committee but may not vote and shall not participate in any discussion or deliberation unless invited to do so by the Committee. The Committee may, at its discretion, include in its meetings members of the Company’s management, and any other personnel employed or retained by the Company or any other persons whose presence the Committee believes to be necessary or appropriate. Notwithstanding the foregoing, the Committee may also exclude from its meetings any persons it deems appropriate, other than non-employee directors.

The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company’s bylaws that are applicable to the Committee.

The Committee may also utilize the services of the Company’s legal counsel or other advisors to the Company, and shall have the authority to engage any outside advisor or consultant of its selection, should the Committee deem it necessary or appropriate to do so.

The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to the advisers retained by the Committee.

The Chairperson shall report to the Board following meetings of the Committee and as otherwise requested by the Chairperson of the Board or by other directors.

IV. Powers and Responsibilities

To fulfill its responsibilities:

1. The Committee shall review, evaluate and report to the Board regarding strategy, plans and goals, as well as progress and performance, of the Company's clinical programs and research and development activities.
2. The Committee shall review and evaluate the infrastructure and resources made available by the Company for its clinical programs and research and development projects, and make recommendations as appropriate if the infrastructure and/or resources are insufficient, in the opinion of the Committee, to accomplish the Company's clinical development programs and research and development projects.
3. The Committee shall identify and discuss significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its clinical programs and research and development activities.

V. Evaluation of Committee Performance

The Committee shall evaluate its own performance on an annual basis, including its compliance with this Charter, and provide any written material with respect to such evaluation to the Board, including any recommendations for changes in procedures or policies governing the Committee.

The Committee shall review and reassess this Charter at least annually and submit any recommended changes to the Board for its consideration.

VI. Publication of Charter

Effective upon the Company's initial public offering, this Charter will be made available on the Company's website and to any stockholder who otherwise requests a copy. The Company's Annual Report to Stockholders or proxy statement shall state the foregoing.